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By Jingda Wang 
 




Peptides have been used as targeting ligands in targeted drug delivery.  Conjugating 
peptides to cytotoxicity agents via a linker to build peptide-drug conjugate (PDC) is a 
promising targeting strategy.  The binding affinity of the peptide ligand and the receptor 
plays a crucial role in the PDC targeted drug delivery.  Although the ligand binding which 
can be used in targeted drug delivery has been established conceptually, the quantitative or 
semi-quantitative contribution of binding affinity in targeting efficiency has not been fully 
explored.  
The optimal range of binding affinity of the peptide for targeted delivery remains 
unknown.  Therefore, there is a lack of knowledge on the relationship between the peptide 
binding affinity and targeted drug delivery efficiency.  The major steps in peptide drug 
delivery include cellular binding, cellular internalization, and tumor cells killing.  In this 
study, three EGFR-targeting peptides with binding affinity levels ranging from 22 nM to 1.25 
μM were selected to study their targeted drug delivery efficiency.  The cellular binding study 
of FITC labeled peptides showed that peptide GE11 with the highest binding affinity had the 
highest cellular binding among three peptides.  PEP11 peptide showed enhanced cellular 
binding compared to the L1 peptide.  Moreover, GE11 also showed the selectivity of cellular 
binding between EGFR-positive cells and EGFR-negative cells.  The cellular distribution 
showed that GE11-FITC could be successfully internalized into cells.  The uptake mechanism 
studies demonstrated that the cellular uptake of GE11-FITC was based on receptor-mediated 
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endocytosis, meaning that the cellular binding of GE11 was able to trigger the endocytosis.  
MMAE, a non-selective anticancer agent, was conjugated to the peptides through a protease-
sensitive linker.  The cytotoxicity assay showed that GE11-MMAE had the highest drug 
delivery efficiency and selectivity of three peptides, with 200 folds lower IC50 value than 
MMAE in EGFR-positive cells and 1000 times lower in EGFR-negative cells.  PEP11-
MMAE also showed an enhanced drug delivery than MMAE and L1-MMAE.  L1-MMAE 
failed to show a significant difference with MMAE.  Cellular binding kinetics results 
revealed that GE11-FITC had a higher rate of cellular uptake than PEP11-FITC.   
In conclusion, in the range from micromolar to the nanomolar, higher binding affinity 
of peptide ligand will contribute to higher cellular binding, targeted drug delivery efficiency, 
and cellular uptake rate.  These results suggest that in EGFR-targeting delivery, the 
nanomolar level binding affinity is necessary for peptides to be used as targeting moiety in 
the targeted drug delivery.  This study provides a starting point for further quantitative 
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CHAPTER 1: INTRODUCTION 
 
Cancer is a group of diseases characterized by uncontrollable cell growth and the 
infiltration of cancer cells into the normal tissue.  Cancer therapy aims to eradicate the cancer 
cells from the human body.  Cancer therapy has remained the same for the last few decades, 
which is surgery followed by exposure to chemotherapy drug or radiation (Sliwkowski & 
Mellman, 2013).  The limitation of cancer therapy development is the severe side effect 
caused by killing both tumor cells and normal cells.  Consequently, the efforts of developing 
a novel cancer therapy have been devoted to reducing the side effects.  For instance, radical 
surgery is substituted by local surgery (Schirrmacher, 2019).  Biological compatible 
molecules are introduced to increase patients’ tolerance (Demaria et al., 2019; Wold & Toth, 
2013).  The accuracy and selectivity have become crucial factors in evaluating the potential 
of cancer therapies (Aboulkheyr Es, Montazeri, Aref, Vosough, & Baharvand, 2018).  The 
key to successful cancer therapy is still making efforts to improve the selectivity between the 
tumor cells and normal cells. 
Cancer-Targeting Therapy 
Targeted drug delivery of anticancer agents provides an opportunity to selectively kill 
cancer cells and minimize the toxicity to normal cells.  Since Paul Ehrlich first proposed the 
concept of “magic bullet”, many attempts have been made to carry the drug to their site of 
action (Ehrlich & Bolduan, 1910).  A targeted drug delivery system (TDDS) is intended to 
carry the drug to the diseased cells but not the healthy cells by using the physiological 
difference between the healthy tissue and cancer.  Further, TDDS can be designed with a 
switch to enable the release of therapeutic agents while exhibiting no efficacy before reaching 
the target.  With higher drug concentration at the target site and lower concentration in the 
healthy tissue, TDDS allows higher drug dose administration and usage of highly potent 
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cytotoxicity agents.  Based on the targeting mechanisms, targeted drug delivery can be 
categorized as passive targeting, physical targeting, or active targeting (Alsaggar & Liu, 
2018).  
Passive Targeting  
The concept of passive targeting is based on the enhanced permeation and retention 
(EPR) effect, which is first raised by Matsumura and Maeda in 1986 (Matsumura & Maeda, 
1986).  The mechanism of EPR effect is that nanomedicines can easily extravasate out of 
tumor blood vessels and accumulate in tumor tissues, not observed in healthy tissues 
(Golombek et al., 2018; Maeda, Bharate, & Daruwalla, 2009).  The size of blood vessel pores 
in tumor tissue has been reported as about 100 nm to 2 μm in diameter so that the 
nanomedicines can escape from the blood vessel (Kalyane et al., 2019).  The lack of 
lymphatic drainage in tumors enables additionally prolonged retention of the nanomedicines 
(Golombek et al., 2018).  However, the EPR effect requires long enough circulation time in 
the human vasculature system.  One method used in the liposome is decorating the carrier 
with polyethylene glycol (PEG) to avoid being captured by the reticuloendothelial system 
(RES).  The stealth liposome successfully prolongs the circulation time and comes up with 
the first FDA-approved commercial available nanomedicine, Doxil (Barenholz, 2012).  
Although the EPR effect can increase the drug concentration in tumors and reduce the side 
effect of Doxil, other nanomedicine designs' clinical outcomes do not show significant 
improvement (Nichols & Bae, 2014).  The nanoparticulate drug delivery systems fail to show 
their efficacy towards solid tumors, even for Doxil.  Several explanations have been made for 
the failure of nanomedicines.  Drug delivery systems are suspected of disintegrating by the 
sheer force of the blood flow, but very stable nanocarriers will trap the drug in the carrier 
(Maeda, 2017).  The absence of lymphatic drainage induces higher interstitial fluid pressure 
(IFP), preventing nanomedicine leaks.  The EPR effect may not occur due to the 
17 
heterogeneity of tumor tissue (D. Sun, Zhou, & Gao, 2020).  Recently, Shrey Sindhwani and 
Warren C. W. Chan et al. discovered that the gaps between the endothelial cells were not 
frequently presented in the tumor blood vessels (Sindhwani et al., 2020).  Instead, the primary 
route of nanoparticles to reach solid tumors was through the active transport of endothelial 
cells.  The role of the EPR effect in cancer drug delivery still needs further exploration. 
 
 
Figure 1.1. Schematic of the Enhanced Permeability and Retention (EPR) effect. (1) Drug-
loaded nanocarrier; (2) gaps between endothelial cells appear in pathological areas (3) (such 
as tumors, infarcts, and inflammations); (4) small molecules of free drug (Torchilin, 2010) 
 
Physical Targeting  
In addition to the EPR effect, more physicochemical condition changes of the tumor 
can be utilized for targeted drug delivery.  The physiological pH is 7.4, while the extracellular 
pH in the tumor is usually below 7 due to the increased level of energy consumption (Webb, 
Chimenti, Jacobson, & Barber, 2011).  The pH-sensitive liposomes and micelles are designed 
to be stable at pH 7.4 and release the drug below pH 7 (Gao, Li, & Lee, 2013; Panahi et al., 
2017).  This switch is usually achieved by ionizing the lipids in a basic or acidic environment, 
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resulting in a conformation change of lipids and the destabilization of liposomes (Felber, 
Dufresne, & Leroux, 2012).  The liposome will undergo the phase change from the lamellar 
phase to the unilamellar phase resulting in the release of the loading drug (Paliwal, Paliwal, 
& Vyas, 2015).   
The increased metabolic activity and proliferation of tumor cells also generated the 
hypoxia environment in tumor tissue and increased level of reactive oxygen species (ROS).  
This higher level of oxidative stress in the tumor is utilized to design the hypoxia targeting 
prodrug (Sharma et al., 2019).  The excessive free radicals will rapidly oxidize the hypoxia-
responsible reductive linkers, causing the reduction-mediated cleavage and the prodrug’s 
destabilization (Brown & Wilson, 2004; Kiyose et al., 2010; Perche, Biswas, Wang, Zhu, & 
Torchilin, 2014).  The hypoxia targeting strategy will be combined with radiotherapy since 
hypoxia will attenuate the oxidation to protect tumor cells from extensive damage (J. Li et al., 
2018; Rey, Schito, Koritzinsky, & Wouters, 2017).    
Active Targeting  
More efforts have been made to explore active targeted drug delivery.  One of the 
promising methods is ligand-based targeted drug delivery (Srinivasarao & Low, 2017).  
Ligand-based targeted drug delivery is based on the idea that the ligand can specifically bind 
to the overexpressed receptor or marker on cancer cells and carry the drug into the target cells 
(Tashima, 2018).  The ligand-receptor interaction is the foundation of the targeted drug 
delivery (Ozturk-Atar, Eroglu, & Calis, 2018; Torchilin, 2010).  Commonly used targeting 
ligands include small molecules, peptides, nucleic acids, proteins, and antibodies (Birrer, 
Moore, Betella, & Bates, 2019; Kue et al., 2016; C. Wang, Liu, Lu, Zhang, & Lu, 2014; Y. 
Wang et al., 2017).  One targeting strategy is to modify the surface of a nanocarrier with 
targeting ligands to build the targeted drug delivery system.  Liposomes, dendrimers, 
polymeric nanoparticles, metal nanoparticles, and lipid carriers are the typical nanocarriers in 
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targeted drug delivery (Kumari, Ghosh, & Biswas, 2016; Majumder, Taratula, & Minko, 
2019).  These nanocarriers are designed to utilize both passive targeting effect with proper 
particle size and active targeting effect with modification of targeting moiety.  Although 
active targeting nanocarriers have been widely researched, to date, no product survives 
through clinical trials.  Some of the issues for active targeting nanocarriers include the off-
target effect (Chithrani, Ghazani, & Chan, 2006; Lazarovits, Chen, Sykes, & Chan, 2015; 
Rosenblum, Joshi, Tao, Karp, & Peer, 2018) and the unavailable industrial scale-up 
production of nanocarriers (Zhang, Cao, & Yuan, 2020).   
A more direct and straightforward way to build the active targeted drug delivery 
system is directly conjugating the targeting ligand to the drug.  Between the drug and the 
targeting ligand, a suitable linker is introduced into the drug delivery system and acts as the 
bridge to connect the drug and ligand.  As shown in Fig 1.2, antibodies and peptides are the 
most typical targeting ligands to conjugate with drug payload, which are called antibody-drug 
conjugate (ADC) and peptide-drug conjugate (PDC).  
   
                         












Targeting ligands            Linker             Payload 
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Antibody-Drug Conjugate and Peptide-Drug Conjugate 
Antibody-Drug Conjugates  
Even though monoclonal antibodies can specifically bind to the target, most do not 
have antitumor activity unless they can alter the signaling patterns or direct immune response.  
By conjugating with the cytotoxicity agents, antibodies are equipped with the weapon to kill 
tumor cells specifically.  The first attempt of ADC in the human clinical trial was in 1983, 
using an anticarcinoembryonic antigen antibody-vindesine conjugate (Ford et al., 1983).  
Since gemtuzumab ozogamicin was firstly approved by FDA in 2000, ADC has been rapidly 
developed with nine products commercially accessible and more than 100 ADCs under 
evaluation in clinical trials worldwide (Chau, Steeg, & Figg, 2019; P. Zhao et al., 2020).    
The molecular mechanism of ADC is mainly based on the antibody-antigen 
interaction (Fig 1.3).  Firstly, the antibody recognizes the antigen on the cell surface and bind 
to the antigen to form an antibody-antigen complex.  Then the antibody-antigen interaction 
triggers the receptor-mediated endocytosis, and the complex is internalized into cells.  After 
being internalized into cells, ADC is processed by protease within the lysosome and releases 
the payload drug.  Finally, the released payload drug can then kill tumor cells by disruption of 
DNA strands, inhibition of microtubule formation, or suppressing RNA polymerase (Chau et 
al., 2019; Tsuchikama & An, 2018; P. Zhao et al., 2020). 
ADCs can selectively eliminate tumor cells with low toxicity to normal tissues due to 
their specificity.  However, there are still issues that remain unresolved for ADC.  
Immunogenicity of antibodies can induce a severe immune response, which can be fatal to 
the patients (Hock, Thudium, Carrasco-Triguero, & Schwabe, 2015).  The high molecular 
weight of antibodies becomes an obstacle to ADC synthesis and purification, which will raise 
the cost of ADC production.  The high molecular weight also prevents the deep penetration of 
the antibody into solid tumors (Lu et al., 2020).  Antibodies have a high binding affinity to 
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the antigens, but extremely high binding affinity may hinder drug delivery (Adams et al., 
2001).  Sellmann et al. took EGFR-antibodies with binding affinities ranging from 15 nM to 
0.08 nM and showed that the highest binding affinity antibody would dramatically decrease 
the cytotoxicity of ADC (Sellmann et al., 2016).  Rudnick et al. showed less tumor 
accumulation of HER-2 targeted antibodies with the binding affinity of 0.56 nM compared to 
270 nM (Rudnick et al., 2011).  Therefore, selecting a proper antibody as the targeting ligand 
remains a crucial step for optimal outcomes.    
  
 
Figure 1.3. Mechanism of cellular binding, internalization and drug release of ADC 
(Tsuchikama & An, 2018) 
 
Peptide-Drug Conjugates  
In addition to antibodies, peptides are another group of commonly used targeting 
ligands.  The design criterion of PDC is very similar to ADC.  Peptides are conjugated to the 
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drug payload through a proper linker to enhance the drug delivery to the target region (Vhora, 
Patil, Bhatt, & Misra, 2015).  In 1993, Rékási et al. first used the luteinizing hormone-
releasing hormone (LHRH) peptide analogs to selectively carry cytotoxicity agent, 
doxorubicin, to LH receptor overexpressed cells (A. Chelariu-Raicu et al.).  The first FDA-
approved PDC is 111In-DTPA-D-Phe1-octreotide (octreoscan), aiming for tumor diagnosis 
and radiotherapy (Bakker et al., 1991; Kontogeorgakos et al., 2007).  Compared to antibodies, 
using peptides as the targeting ligand shows several advantages.  Relatively low molecular 
weight allows versatile designing, easy synthesis, flexible structure modification, and high 
drug loading efficiency (Hoppenz, Els-Heindl, & Beck-Sickinger, 2020; Y. Liang et al., 
2018).  Peptides have good biocompatibility without generating severe immune response 
(Gilad, Firer, & Gellerman, 2016; M. Liang et al., 2017).  Furthermore, they have the 
potential to promote penetration into solid tumors or cells (Cox, Kintzing, Smith, Grant, & 
Cochran, 2016; Habault & Poyet, 2019).  Two types of peptides have been used in PDC, cell-



















































































































































































































































































































































































































































































































































































































































































































































































Cell-penetrating peptide.  CPP is a group of positively charged short peptides that 
can penetrate through physiological membranes and deliver various cargos into cells 
(Derakhshankhah & Jafari, 2018).  It is reported that CPP can translocate different molecules 
into cells, especially biological macromolecules (Mae & Langel, 2006).  The internalization 
mechanism of CPP is still under debate.  Direct penetration, clathrin-mediated endocytosis, 
caveolae-mediated endocytosis, and macropinocytosis are possible mechanisms for CPP 
internalization (Derakhshankhah & Jafari, 2018; Gestin, Dowaidar, & Langel, 2017).  Most 
CPPs cannot specifically deliver the drug to tumor cells, which becomes the major hurdle of 
CPP-based drug delivery.  One strategy proposed to overcome the non-specific delivery of 
CPP is to design activatable CPP (Bode, Hansen, Oerlemans, van Hest, & Lowik, 2015; 
Cheng et al., 2015).  Activatable CPP is designed by shielding the side chain of lysine with an 
enzyme cleavable group and temporarily inactivating the CPP.  When activatable CPP 
reaches the tumor site, an enzyme will cleave the shielding group and activate CPP.  The 
specificity of drug delivery is achieved by selecting a proper enzyme, which is abundant in 
tumor tissue. 
Cell-targeting peptide.  CTP has relatively high binding affinity and specificity to the 
target cells, and it can carry the drug to the cells based on the ligand-receptor interaction.  
Over the last few decades, CTPs have attracted considerable attention as promising ligands to 
specifically deliver therapeutic and diagnostic agents (M. Liang et al., 2017; Mousavizadeh, 
Jabbari, Akrami, & Bardania, 2017; Y. Wang et al., 2017).  Both CTP and CPP can be used 
for drug delivery into the cells, but the mechanism of internalization is quite different.  Eunji 
Jo et al. compared the in vitro targeted drug delivery to the EGFR and integrin overexpressed 
cells between CTP and CPP modified nanoparticles (Jo et al., 2018).  In U87MG and MDA-
MB-231 cells, they found that the CTP-modified nanoparticles showed a higher level of 
endocytosis than CPP-modified nanoparticles.  Besides, CTP could effectively transport the 
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nanoparticle from the endosome to cytosol, while CPP was trapped in the endosome.  Thus, 
CTP has greater potential in drug delivery compared to CPP.   
Among all the CTPs, the integrin αvβ3−targeting Arg-Gly-Asp (RGD) motif is the 
most studied due to its inherent safety, biocompatibility, and targeting ability.  Integrin αvβ3, 
as the target of RGD, is overexpressed in many types of cancers, including melanoma, 
prostate cancer, pancreatic cancer, cervical cancer, and glioblastoma (Desgrosellier & 
Cheresh, 2010).  Moreover, integrin αvβ3 is reported to express on endothelial cells, which are 
the target of antiangiogenic therapies (Potente, Gerhardt, & Carmeliet, 2011; Zitzmann, 
Ehemann, & Schwab, 2002).  This broad spread expression pattern enables the wide 
application of RGD in cancer treatment.  RGD has been used to conjugate to a wide range of 
small molecules (doxorubicin, paclitaxel, Platinum complexes, camptothecins, salicylic acid, 
etc.), peptides, and imaging probes (Chen, Plasencia, Hou, & Neamati, 2005; Dal Pozzo et 
al., 2010; Hu et al., 2015; Katsamakas, Chatzisideri, Thysiadis, & Sarli, 2017).  Furthermore, 
the iRGD (CRGDKGPDC) peptide has been developed based on RGD peptides to facilitate 
tumor penetration.  iRGD will first bind to αv integrins and be cleaved by proteases to expose 
the neuropilin-1 (NRP-1)-binding CRGDK/R, which effectively triggers the tumor 
penetration process (Yin et al., 2017).  The combined activity of cell targeting and penetrating 
makes iRGD a very promising peptide ligand for drug delivery (Zuo, 2019). 









Table 1.2  
Current Cell-Targeting Peptides for PDC in Literature 
Cell targeting 
peptides 

















































































& Jain, 2018) 
 
Payloads for ADC and PDC 
The payloads of ADC and PDC are the antitumor functional molecules, which are 
mostly cytotoxicity agents.  It is estimated that only 1.56% of administered molecules can 
reach the target cells if each step’s efficiency in the ADC mechanism can reach 50% 
(biodistribution, antigen binding, internalization, the release of payload, intracellular stability 
of payload, and payload efficacy) (Teicher & Chari, 2011).  The payload of ADC and PDC is 
required to be highly potent in order to maximize the efficacy of treatment and kill tumor 
cells substantially (Tsuchikama & An, 2018).  These payloads are often too toxic for 
traditional chemotherapy and lack selectivity for tumor cells (Duerr & Friess, 2019).  Thus, 
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the targeting ligand is introduced to deliver the drug to the target tumor cells specifically.  
Two categories of cytotoxicity drugs have been selected as the payload of ADC and PDC: 
DNA-targeting payloads and tubulin targeting payloads (Duerr & Friess, 2019; McCombs & 
Owen, 2015).  The first group of molecules will bind to the cellular DNA to inhibit the 
transcription and replication of DNA, resulting in apoptosis.  Several DNA-targeting 
payloads have progressed into clinical trials, including calicheamicin, SJG-136, SN38, 
adozelesin, and indolinobenzodiazepine dimers (Lambert, 2016).  The first FDA-approved 
ADC, gemtuzumab ozogamicin, uses calicheamicin as the payload.  Even though this class of 
payload has achieved success in clinical trials, the lack of sufficient solubility in aqueous 
conditions limits the wide use of these DNA-targeting payloads.   
The second class of cytotoxic payload is anti-mitotic agents, including paclitaxel 
(PTX), auristatin, and maytansinoids.  Auristatin derivatives, including monomethyl analogs 
monomethyl auristatin E/F (MMAE and MMAF), are the largest class of ADCs payloads in 
clinical development.  Both MMAE and MMAF are the synthetic analogs of dolastatin 10 
extracted from the Indian Ocean sea hare.  They can bind to tubulin to inhibit the microtubule 
dynamicity and terminate cells in the G2/M phase of the cell cycle (Breij et al., 2014; 
Zhuanglin Li et al., 2019; Vaishampayan et al., 2000).  By inhibiting the mitotic, MMAE and 
MMAF can suppress cell proliferation and cause apoptotic cell death.  MMAE has been used 
as a payload in brentuximab vedotin, glembatumumab vedotin, and enfortumab vedotin 
(Rosenberg et al., 2019).  MMAF is used in depatuxizumab mafodotin and belantamab 
mafodotin (Chau et al., 2019; Lonial et al., 2020).  Most of these ADCs have been approved 
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Linkers Conjugation Strategies in ADC and PDC 
A linker is a critical component in ADC and PDC, which connects the drug payload 
with the targeting ligand.  As the linker of ADC and PDC, simply linking payload and ligand 
is not the only requirement.  Several prerequisites have been proposed for linker selection 
(Jain, Smith, Ghone, & Tomczuk, 2015).  Firstly, it is required to be stable in plasma for a 
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period to prevent the premature release of the cytotoxic payload.  After internalizing into 
cells, a linker should release the payload drug without impairing the drug activity.  
Additionally, a linker may also need to optimize the physicochemical property of the 
conjugates, especially for the hydrophobic chemotherapy drug.  Up to now, no universal 
linker for ADC has been discovered.  The linker of ADC should be designed or selected 
according to the chemical structure of the payload. 
The recent linkers fall into two main categories: non-cleavable and cleavable (Bargh, 
Isidro-Llobet, Parker, & Spring, 2019; Jain et al., 2015; Nolting, 2013).  One notable example 
of the non-cleavable linker is the cysteine-maleimide linker.  The maleimide group can easily 
react with the free thiol group in cysteine by forming a stable thioester bond (Fig 1.4).  The 
common maleimide-type linker includes maleimidocaproyl (mc) and maleimidomethyl 
cyclohexane-1-carboxylate (mcc).  All the MMAE and MMAF-containing ADCs in the 
market right now use the “mc” linkage strategy.  Non-cleavable linkers provide a stable 
linkage between the drug and the antibody, but the drug release is limited due to the absence 
of a release mechanism.  For non-cleavable linkers, the mechanism of drug release is by the 
complete degradation of the ligand into amino acids in the lysosome.  As a consequence, the 
released payload is expended with an additional amino acid from the targeting ligand.  The 
localization of the conjugates to the lysosome is the key factor for the drug release of the non-
cleavable linker, but the cell permeability is limited with the charged amino acid appendage 
for the non-cleavable linkers.  Compared to the non-cleavable linkers, cleavable linkers 
become more favorable in drug design.  
Cleavable linkers use the inherent properties of tumor cells to release the payload 
drug selectively.  Three possible mechanisms have been applied to the payload release: 1) 
pH-sensitivity, 2) protease-sensitivity, and 3) glutathione-sensitivity (Bargh et al., 2019).  In 
endosomal (pH = 5–6) and lysosomal (pH = 4.8) compartments, pH is lower than cytosol (pH 
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= 7.4).  This physiological difference of pH can trigger the hydrolysis of the acid-labile group 
within the linker, such as a hydrazone.  The hydrazone linker was the earliest successful 
linkage strategy used in the pioneering ADC, Gemtuzumab Ozogamicin (Singh & Erickson, 
2009).  But it is believed that the heterogeneous nature of the conjugate and the instability of 
the hydrazone linker lead to the voluntary withdrawal of Gemtuzumab Ozogamicin from the 
market in 2010 (Jain et al., 2015).  One way to improve the stability of the linker is 
conjugating the hydrazone linker with polymers or maleimide groups (Lidicky et al., 2020). 
The release mechanism of second group linkers is protease-triggered hydrolysis.  
Protease is rich in the lysosome of cells but remains absent outside cells (Dubowchik, 
Mosure, Knipe, & Firestone, 1998).  Specific peptide sequences can be recognized and 
cleaved by a protease.  The representative peptide sequence is a dipeptide, valine-citrulline 
(vc).  Dubowchik and coworkers were the first to use this dipeptide in a three components 
linker (mc-vc-PABC) and applied this linker in the doxorubicin-based ADC (Dubowchik et 
al., 2002; Dubowchik et al., 1998).  Later, Peter D Senter and Eric L Sievers used this linker 
in the first FDA-approved MMAE-based ADC, Brentuximab Vedotin (Senter & Sievers, 
2012).  The three-component linker showed promising in vivo stability, and it could be 
readily cleaved after entering the cells.  Currently, it has become the most typical linker for 
MMAE-based ADCs.   
The third type of linker is the disulfide bond linker.  The release mechanism of the 
disulfide bond relies on the higher intracellular glutathione concentration than plasma.  
Furthermore, the oxidative stress induced by tumor progression results in elevated GSH 
levels compared to healthy tissue, which adds an extra level of selectivity towards cancer 
cells.  Recently, a direct disulfide-bonding conjugation strategy has been applied between 
antibody cysteine residues and maytansinoid drug (DM1) (Pillow et al., 2017).  In the 
research, the in vivo half-life of the disulfides was within one day.  By shielding disulfides 
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with a methyl group on one side of the disulfide bond, the solvent-exposed sites were 
reduced, and the in vivo stability of the disulfide bond was extended to more than four days.  
Overall, these three linkage strategies have different release mechanisms.  Selecting a linkage 
strategy is dependent on the chemical structure of the payloads. 
   
 
Figure 1.4. Schematic mechanism of maleimide thiol conjugation 
 
 
Figure 1.5. Schematic chemical structure of Mcc-Acyl-Hydrazone linker 
 
 





Epithermal Growth Factor Receptor Targeting 
The ideal target for drug delivery should be overexpressed on the tumor cells’ surface 
with no expression or low expression in the normal tissue.  Epithermal growth factor receptor 
(EGFR) is a transcellular receptor tyrosine kinase of the ErbB family (Normanno et al., 2006; 
Sigismund, Avanzato, & Lanzetti, 2018).  The extracellular domain of EGFR is the binding 
site of its ligand EGF and the cytoplasmic domain is the tyrosine kinase domain (Dokala & 
Thakur, 2017).  EGFR is highly expressed in various human cancers, including non-small cell 
lung cancer (NSCLC), breast cancer, bladder cancer, glioblastoma, prostate cancer, cervical 
cancer, etc. (Liu, Wang, Zhang, & Ma, 2017)  The EGFR signaling is closely related to tumor 
cell proliferation and tumor angiogenesis.  Many attempts have been made in anti-EGFR 
cancer therapy strategy, including monoclonal antibodies, such as cetuximab and 
panitumumab, and small molecule inhibitors, such as gefitinib, erlotinib, lapatinib, 
Dacomitinib, Osimertinib, and afatinib (Mazzarella, Guida, & Curigliano, 2018; Xu, Johnson, 
& Grandis, 2017).  Peptide-based targeted drug delivery is also a promising strategy in anti-
EGFR cancer therapy.  As shown in Table 1.4, EGFR-targeting peptide ligands have been 
discovered through different discovery routes.  These peptide ligands can specifically bind to 
the extracellular domain of EGFR.  Upon binding to EGFR, the ligands will be internalized 
along with EGFR through receptor-mediated endocytosis (Tomas, Futter, & Eden, 2014).  
Polymers, radionuclides, cytotoxicity drugs, and nanocarriers are the common cargoes or 
payloads for the EGFR-targeting peptides (Jiao, Zhao, Han, Zhang, & Wang, 2020; 
Kopansky, Shamay, & David, 2011; Lin et al., 2019; Zhou et al., 2020).  These EGFR-
targeted drug delivery systems exhibit their potential in selective drug delivery and show 
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CMYIEALDKYAC EBP B-loop of EGF N.A (Ai et al., 2011) 
YHWYGYTPQNVI GE11 phage display 22 














8.7×103 (Song et al., 2009) 
KLARLLT L1 D4 analog 1.25×103 
(Williams, Sable, 
Singh, Vicente, & 
Jois, 2018) 
 
Statement of Problem 
Although the lower molecular weight of peptides offers several advantages, it also 
brings drawbacks to the targeted drug delivery (Muro, 2012), such as the relatively weak 
binding affinity of the peptide to the targets.  Binding affinity is defined by the equilibrium 
dissociation constant (kD).  Lower kD represents a higher binding affinity to the target.  
Typically, the kD value of antibody is in the range of nanomolar to picomolar.  But for 
peptides, the kD value falls into the range from micromolar to nanomolar, which is lower than 
antibody (Srinivasarao & Low, 2017; Uddin et al., 2019; Zer et al., 2017).  Since peptides 
have smaller molecular weight, simpler structure, and more flexible conformation than 
antibodies, limited interactions and interaction areas between peptides and target result in 
fewer high-quality binding regions and lack binding pocket (S.-H. Wang & Yu, 2018).  
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Higher binding affinity leads to a higher dynamic concentration of binding ligand on the 
target and longer retention time for ligand-receptor interaction, which theoretically will 
enhance the drug delivery.  But excessive-high binding affinity ligands will not easily detach 
from the receptor and prevent new ligands from binding to the same receptor (Adams et al., 
2001).  It is also possible that the relationship between binding and targeting capability 
reaches a plateau within a certain range of affinity, so the targeted drug delivery efficiency 
may not be significantly increased by using a high binding affinity ligand.  Furthermore, as 
another class of targeting ligands, peptides may require a different level of binding affinity 
compared to antibodies.  But the optimized range of binding affinity of peptides for targeted 
drug delivery is still unknown.  The relationship between the binding affinity and targeted 
drug delivery needs to be investigated to provide guidance for the design and development of 
peptide ligand and drug delivery system.   
PDC is a promising platform for targeted drug delivery.  The binding affinity of the 
targeting peptide ligand is the foundation of PDC-targeted drug delivery.  In this case, it is 
very meaningful to explore if higher binding affinity peptides have a higher potential in 
targeted drug delivery of PDC.  
Hypothesis 
The binding affinity of the peptide ligand has an optimal range with a minimum threshold and 
a maximum limit for effective targeted drug delivery.  
Aims 
This dissertation aims to compare the targeted drug delivery of peptides with different 
levels of binding affinity.  Three EGFR-targeting peptide ligands (1) L1 (KLARLLT, 
kd=1.25μM) (Williams et al., 2018), (2) PEP11 (WSGENGPGFYDYEA, kd=252nM) 
(Sachdeva et al., 2019) and (3) GE11 (YHWYGYTPQNVI, kd=22nM) (Zonghai Li et al., 
2005) are selected for this study.  The ligand peptides will be synthesized, characterized, and 
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conjugated with a drug or fluorescence probe to compare their difference in the targeted drug 
delivery.  The research objectives will be achieved through the following specific aims: 
1. To synthesize and characterize the EGFR targeting peptides and PDCs.  The peptides 
will be either conjugated with MMAE through the mc-vc-PABC linker to build PDCs 
or conjugated with FITC to trace the peptides' behavior.   
 
2. To determine the contribution of peptide binding affinity to the cellular binding.  The 
cellular binding will be compared between three FITC-labeled peptides.  
  
3. To demonstrate that the peptides can be internalized into cells.  The cellular 
distribution and cellular uptake mechanism studies will be conducted for this purpose.  
 
4. To correlate the contribution of peptide binding affinity to the drug delivery by 
comparing the cytotoxicity and selectivity of PDCs.  The cytotoxicity of PDCs will be 
compared in the EGFR-positive cell lines, and selectivity of PDCs will be compared 
between the EGFR-positive cells and EGFR-negative cells. 
 
5. To investigate the contribution of binding affinity to the rate of cellular uptake.  The 


















CHAPTER 2: SYNTHESIS AND CHARACTERIZATION OF PEPTIDES AND PDC 
 
Introduction 
Peptides are synthesized by forming amide bonds between amino acids.  Bruce 
Merrifield invented solid-phase peptide synthesis (SPPS), which is the most common method 
for synthesizing peptides (Amblard, Fehrentz, Martinez, & Subra, 2006).  Compared to the 
liquid-phase peptide synthesis, SPPS simplifies the purification during the synthesis and 
allows the development of automatic peptide synthesis instruments.  In SPPS, the peptide is 
synthesized from C-terminal to N-terminal.  The first amino acid of the peptide is usually pre-
conjugated to the loading resin.  The resin is an insoluble polymer and serves as the solid 
support of amino acids and peptides.  The carboxyl group of amino acids established the 
amide bond to the resin, and the amide group of amino acids is ready for the coupling to the 
next amino acid.  HBTU can form a stabilized HOBt leaving group with the negatively 
charged carboxyl group by generating a HOBt ester.  The highly active ester can be easily 
replaced by the amino group and form the desired amide bond (Jaradat, 2018). When all the 
amino acids are coupled onto the resin, the peptide will be cut off from the resin by using the 
cleavage cocktail. 
In order to trace the peptides' behavior, a fluorescent probe or a radionuclide is used to 
label the peptide.  Both approaches can offer a strong signal for detection to show the 
location of peptides.  Additionally, radiolabeling peptides have the potential to be 
radiotheranostic molecules, which can simultaneously detect and kill tumor cells (Fani, Peitl, 
& Velikyan, 2017).  But to operate radiolabelling peptides, specific equipment for protection 
and detection is required.  Fluorescent labeling peptides can be used for in vivo biomedical 
imaging, protein binding, and localization studies.  Fluorescent dye-labeled peptides can be 
visualized using fluorescence microscopy, confocal microscopies, or other fluorescence 
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visualization techniques.  Fluorescent labeling is easy to handle and detect, but additionally 
synthesis and peptide structure modification are required.  Also, the chemical structure of the 
molecule of interest is altered.   
MMAE is a derivative of dolastatin 10, which is a pentapeptide isolated from the 
mollusc Dolabella auricularia.  Lack of selectivity and high toxicity limits the clinical 
activity of MMAE (Vaishampayan et al., 2000).  Consequently, MMAE is generally 
conjugated with a targeting ligand to be selectively delivered to the tumor.  The most 
common linker for MMAE-based conjugates is the three components linker, mc-vc-PABC 
linker(Jain et al., 2015).  The first component, “mc”, which stands for maleimidocaproyl, is 
used to conjugate to the free thiol group of cysteine from antibody or peptide (Fig 2.1).  The 
short term “vc” stands for a dipeptide sequence, valine-citrulline (Val-Cit).  The amide bond 
at the C-terminal of the dipeptide can be cleaved by Cathepsin B protease.  When the 
dipeptide is cleaved, PABC-MMAE will be released.  The last component of the linker PABC 
is a spacer to separate the drug with the cleavable bond.  It is used to protect the drug from 
the destruction of the cleavage reaction.  Once the dipeptide is cleaved, PABC will fragment 
and release the unmodified MMAE molecule (Fig 2.2).  The mc-vc-PABC linker has been 
widely used in the MMAE based ADCs (Gikanga, Adeniji, Patapoff, Chih, & Yi, 2016; C. Li 
et al., 2020) .  
 
         
Figure 2.1. Structure of peptide-mc-vc-PABC-MMAE 
 
 Linker cleavage site by 
Cathepsin B 
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Figure 2.2. Schematic mechanism of MMAE release from PABC-MMAE 
 
Materials 
All the amino acids, resins, coupling agents, and cleavage agents were purchased 
from Chem-Impex (Wood Dale, IL, USA).  MC-VC-PAB-MMAE was purchased from 
eNovation Chemicals LLC (Bridgewater Township, NJ).  5- fluorescein isothiocyanate 
(FITC) was purchased from Anaspec (Fremont, CA).  Diethyl ether, N, N`-
dimethylformamide (DMF), and dichloromethane (DCM) were purchased from Fisher 
Scientific (Pittsburgh, PA, USA).  Peptide reaction vessels were purchased from Torviq 








Synthesis of Peptides  
The peptides were synthesized by using standard Fmoc solid-phase synthesis 
(Amblard et al., 2006; Jaradat, 2018).  In order to conjugate the peptide with the maleimide 
linker, one cysteine amino acid was introduced into all three peptide sequences at C-terminus 
(L1:KLARLLTC; PEP11:WSGENGPGFYDYEAC; GE11:YHWYGYTPQNVIC).  In this 
study, Fmoc-L-Cys(Trt)-2-chlorotrityl resin was used as the loading resin with cysteine pre-
loaded on the resin.  The resin (0.3 mmol) was weighed and transferred into the reaction 
vessel.  The resin (0.2 mmol) was placed in DMF (6ml) to swell for 30 min.  Piperidine DMF 
solution (20%) was added into the reaction vessel to remove the 9-Fluorenylmethoxycarbonyl 
(Fmoc) protecting group of amino acids on the resin and shake for 30 minutes.  The resin was 
washed with DMF and DCM three times each.  The released free amide group will be 
conjugated to the carboxyl group of the next amino acid with the aid of coupling reagents.  
HOBt, O-benzotriazol-1-yl-N,N,N ,N -tetramethyluronium hexafluorophosphate (HBTU), 
DIPEA, and amino acids were added to the reaction vessel.  The deprotection and coupling 
reaction will be repeated until all the amino acids are coupled to the resin.  The molar ratios 
of resin to amino acids and coupling agents were 1 to 6 to ensure all free amide groups on the 
resin were fully coupled.  Each coupling lasted for 3 hours.  Upon completing all couplings, 
the peptide was cleaved from the resin using the cocktail of trifluoroacetic acid (TFA), 
deionized water, phenol, and triisopropylsaline (TIPS) with the molar ratio of 88:5:5:2.  Cold 
diethyl ether was used to precipitate and wash the peptides.  Then the peptides were dissolved 
in water.  The peptide aqueous solution was frozen in a -80℃ freezer and lyophilized to 
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Figure 2.3. Chemical structure of A. HBTU; B. HOBt; C. DIPEA 
 
              
Figure 2.4. Mechanism of coupling reaction by HBTU/DIPEA 
 
Synthesis of PDCs Reaction Schemes 
Peptides were conjugated with MMAE through maleimide–cysteine linkage 
(Hamblett et al., 2004; Lyon, Meyer, Setter, & Senter, 2012).  The maleimide and free thiol 
group can easily undergo Michael’s addition to form the sulfide bond (Martinez-Jothar et al., 
2018).  Peptides and mc-vc-PABC-MMAE (1:1, w/w) were dissolved separately in 
water/Acetonitrile (50%/50%, V/V) solution.  The pH of solutions was adjusted between 6.5-
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7.5 by using hydrochloride acid and sodium hydroxide.  After mixing two solutions, the pH 
was adjusted again to 6.5-7.5.  The solution was kept shaking for 1 hour and the solution was 
lyophilized to acquire the product.   
Synthesis of FITC-Conjugated Peptides  
Aminohexanoic acid (Ahx) was coupled to the peptide at N-terminal using the same 
procedure of peptide coupling in peptide synthesis.  Then the Fmoc protected Ahx was 
deprotected using 20% piperidine DMF solution for 30min.  Three equivalents of FITC and 
ten equivalents of DIPEA were dissolved in DMF and mixed with resin in the reaction vessel.  
The reaction vessel was kept shaking in the dark overnight.  The FITC-conjugated peptides 
were cleaved by the cocktail of TFA, deionized water, phenol, and TIPS with a molar ratio of 
88:5:5:2.  The product was precipitated and washed by cold diethyl ether and lyophilized 
(Joshi et al., 2016).  
 
      A                                    B                                        C                 
 
Figure 2.5. Reaction scheme of FITC-Ahx conjugation. A. Ahx-Peptide; B. FITC; C.FITC-
Ahx-Peptide 
 
Characterization of Synthesized Molecules by HPLC 
The purity of the synthesized products was determined using reverse-phase HPLC 
(Agilent 1100) system, consisting of G1312A bin pump, G1329A autosampler, and G1315A 
DAD detector.  The used HPLC column was Agilent Zorbax C18, 3.5 μm, 4.6×150 mm.  
The peptides were detected at the wavelengths of 210 nm, 230 nm, and 280 nm.  The 
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wavelengths of 210 nm and 230 nm were the absorbance wavelengths of the amide bond, and 
280 nm was the absorbance wavelength of aromatic rings.  The mobile phase for HPLC 
analysis was composed of deionized water with 0.1%TFA as water phase (A) and acetonitrile 
with 0.1%TFA as organic phase (B).  A linear gradient from 90% to 10% of water phase with 
a flow rate of 1 ml/min was used as PDCs and FITC-labeled peptides HPLC elution method.  
The purity of the peptide was determined by the HPLC area under the peak ratio of peptide 
peak over all the peaks.  Purification of the synthesized product was conducted by collecting 
the product HPLC peak.   
Characterization of Synthesized Molecules by Mass Spectrometry 
All the molecules were dissolved in a mixture of water and methanol with a 
concentration lower than 50 ppm.  The molecules were analyzed by Varian 320-MS 
Electrospray Ionization Tandem Quadrupole mass spectrometer and Thermo Scientific LTQ 
XL linear ion trap mass spectrometer with a flow rate of 50 μL/min.  The weight over charge 
ratio of charged ions was used to verify the molecular weight of molecules.   
Stability of PDCs in Cell Culture Medium 
The stability of three PDCs in DMEM cell culture medium containing 10% FBS was 
determined at 37 C and the samples taken at different time intervals were quantified by 
using HPLC.  Three PDCs were dissolved in DMSO to prepare the stocking solution with 20 
mg/ml.  PDC stocking solution (10 μl) was added into a 1.5 ml centrifuge tube which 
contains 90 μl cell culture medium, to make the final concentration 2 mg/ml.  Three 
centrifuge tubes from each PDC group were taken out from the incubator at each time point, 
and 100 μl acetonitrile was directly added into each tube to precipitate the proteins.  Then the 
tubes were centrifuged at 16000 rpm for 5 minutes, and the supernatant was transferred into 
the HPLC vials.  The precipitate was washed with 100 μl acetonitrile and sonicated for 5 
minutes.  The supernatant was collected into the same HPLC vials and analyzed by using 
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HPLC.  The HPLC peak area was calculated, and the peak area ratio of each time point over 
time zero was calculated to show the stability of PDCs.  
Results and Discussions 
Peptide Synthesis and Characterization 
The characterization of the synthesized molecules was conducted using HPLC 
analysis and ESI mass spectrometry.  The ESI mass spectra of three PDCs were shown in Fig 
2.6, Fig 2.7, and Fig 2.8.  The ESI mass spectra of three FITC-labeled peptides were shown 
in Fig 2.9, Fig 2.10, and Fig 2.11.  The HPLC spectra of PDCs after purification were shown 
in Fig 2.12, Fig 2.13, and Fig 2.14, and the purity of the FITC labeled peptides was shown in 
Fig 2.15, Fig 2.16, and Fig 2.17.  The calculated molecular weight of charged ions and 
purities of PDCs and FITC labeled peptides were summarized in Table 2.1 and Table 2.2, 
respectively.  The molecular ion peaks in the mass spectra agreed with the calculated mass, 
showing that the PDCs and FITC labeled peptides were successfully synthesized.  The purity 
of all PDCs was above 90% and FITC-labeled peptide was above 80%.   
In this study, we used the Fmoc to protect the amine group of amino acids.  Compared 
to the tert-butoxycarbonyl (Boc) protection strategy, the Fmoc protection strategy has 
advantages in (1) more straightforward deprotection method without using TFA and (2) 
producing indicators to show the process of reaction (Amblard et al., 2006; Behrendt, White, 
& Offer, 2016).  HBTU, HOBt, and DIPEA were used as the coupling reagents in this 
research.  The intention of adding coupling reagents was to activate the carboxyl group and 
accelerate the reaction.  The coupling reaction of tryptophan and arginine was repeated twice 
to ensure that the amino acids were fully coupled.   
The peptides were further conjugated with FITC at N-terminus through the Ahx 
linker.  Ahx was used as the spacer to separate the bulky fluorescence probe with the peptide 
and prevent the undergoing cyclization leading to the removal of the nearby amino acid 
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(Jullian et al., 2009).  The FITC-labeled peptides were used later in the cellular binding and 
uptake studies of Chapter 3.4.1 and Chapter 3.4.2.   
C-terminus of three peptides was used to conjugate with the mc-vc-PABc linker.  
According to the literature, the C-terminus of three peptides had been modified with either 
polymer or drug linker.  This modification did not impair the cellular binding of three 
peptides (Petho et al., 2020; Sachdeva et al., 2019).  PDC molecules were used in the 




































































































































































































































































































































Table 2.1  
Ionized Molecular Weight and the Purity of PDCs 
molecules Calculated  (M+ 3H)
3+




/3 ion  purity% 
L1-MMAE 745.6 745.5 94.8 
PEP11-MMAE 1004.8 1004.6 94.0 
GE11-MMAE 987.8 987.6 90.2 
 
Table 2.2  
Ionized Molecular Weight and the Purity of FITC-Labeled Peptides 
molecules Calculated (M+2H)
2+
/2 ion Observed (M+2H)
2+
/2 ion  purity% 
L1-FITC 710.6 710.3 83.2 
PEP11-FITC 1099.4 1099.2 79.6 
GE11-FITC 1074.4 1074.0 80.8 
 
Stability of PDCs in Cell Culture Medium 
The peptidase in FBS can cause the rapid proteolytic degradation of peptides (Yi, 
Warunek, & Craft, 2015).  The stability of three PDCs in 10% FBS containing DMEM cell 
culture medium was determined to confirm that PDCs can survive in the medium before 
uptake into the cells.  Fig 2.18 showed the stability of PDCs in the 10% FBS containing 
DMEM cell culture medium.  L1 peptide showed the highest degradation rate with 40% 
survived in the cell culture medium at 24 hours and 20% at 72 hours.  PEP11 and GE11 
showed relatively higher stability than L1 with more than 40% survived at 72 hours.  
Typically, most peptide conjugates started to be uptake into cells right after the incubation 
and finished within 8 hours (Pinilla-Macua & Sorkin, 2015; N. Zhao et al., 2017).  For three 
PDCs, more than 60% were survived after 8 hours, indicating that a significant amount of 
PDCs was stable in the cell culture medium during the cellular assay.  
In summary, three EGFR-targeting peptides were successfully synthesized through 
SPPS.  Peptides were further conjugated with FITC and MMAE.  The FITC-labeled peptides 
and PDCs were characterized by ESI mass spectrometry and HPLC showing correct ion 
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molecular weight and high purity.  The stability assay result of PDCs demonstrated that 
PDCs were stable in the cell culture medium 
 
           




































































CHAPTER 3: COMPARISON OF CELLULAR TARGETING DELIVERY BETWEEN 
THREE PEPTIDES  
 
Introduction 
The goal of targeting delivery is to deliver the drug to the target cells specifically.  
The peptide receptor interaction is the driving force of peptide-targeted drug delivery.  
Different binding assays have been designed to determine the peptide receptor interaction, 
and they can be categorized into two levels, the molecular level binding assays and cellular 
level binding assays (Yakimchuk).  Common molecular level binding assays include surface 
plasmon resonance (SPR), nuclear magnetic resonance (NMR), X-ray crystallography, and 
isothermal titration calorimetry (ITC), etc.  These molecular-level binding assays can provide 
information on the binding affinity of peptides to the receptor proteins.     
Beyond the molecular level binding, peptides need to bind to the target cells and carry 
the drug into cells.  Cell binding assays can provide the knowledge of how peptide bind and 
uptake by the target cells (Pollard, 2010; Zhai, Zhou, Du, & Gao, 2019).  With the help of a 
fluorescent probe or radionuclide, peptides can be detected by flow cytometer, fluorescence 
microscope, or confocal laser scanning microscope.  Flow cytometry can quantitatively 
measure the fluorescent intensity of a cell population, but it cannot provide the cellular 
distribution of the peptide ligand.  Fluorescence microscopy can offer visual images of 
peptides binding and uptake by cells.  Using the laser as the light source, the confocal laser 
scanning microscope has higher sensitivity, resolution, and contrast of fluorescence signal 
than the conventional microscopy (Kang et al., 2014; Sevcik, Salazar, Diaz, D'Suze, & 
Vazquez, 2013).  These visual methods can be used for qualitative and semi-quantitative 
analysis of peptides’ cellular binding, but they are not suitable for the data-based quantitative 
analysis unless a large number of images are acquired.  
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In most cases, the endocytosis of peptides occurs when the peptide ligands physically 
bind to the receptor (Copeland, Pompliano, & Meek, 2006).  The receptor-mediated 
endocytosis is the primary pathway of peptides trafficking into the cells (Kornilova, 2014; 
Schwartz, 1995).  Endocytosis pathways include clathrin-mediated endocytosis, caveolae-
mediated endocytosis, phagocytosis, and pinocytosis (Mulcahy, Pink, & Carter, 2014).  
ATPase activity, which is the primary energy source of active transport, can be significantly 
inhibited by low temperature (Lodish H, 2000; Pan & Elmquist, 2007).  The comparison of 
cellular uptake under body temperature and 4 ℃ can determine whether the peptide uptake is 
energy-dependent or not.  Another feature of receptor-mediated endocytosis is that it is 
saturable and independent of the concentration gradient.  Free peptides can block the 
excessive peptides binding to the receptor and act as the competitive inhibitor of receptor-
mediated active transport.  Endocytosis inhibitors are also used to study the cellular uptake 
mechanism of peptides.  Dynasore is a typical inhibitor of clathrin-mediated endocytosis by 
suppressing the activity of dynamin protein (Kirchhausen, Macia, & Pelish, 2008).   And 
methyl-β-cyclodextrin (MBCD) is the inhibitor of caveolae-mediated endocytosis by 
depleting the cholesterol on the cell membrane (Mahammad & Parmryd, 2015; Moriyama, 
Marquez, Wakatsuki, & Sorokin, 2007).   It is believed that clathrin and caveolae-mediated 
endocytosis are the dominant mechanisms of EGFR-mediated endocytosis (Tomas et al., 
2014). 
As a targeted drug delivery system, PDC should be able to carry the drug to the target 
cells and release the drug to kill tumor cells.  The cytotoxicity of PDC molecules is a critical 
aspect of targeted drug delivery.  To determine the cell death caused by the damage of PDCs, 
numerous cell viability assays have been used, such as 3-(4,5-dimethylthiazol-2-yl)-2–5-
diphenyltetrazolium bromide (MTT) assay, 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethyl-
thiazoly)-3-(4-sulfophenyl) tetrazolium, inner salt (MTS) assay, lactate dehydrogenase 
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(LDH) cytotoxicity assay and sulforhodamine B (SRB) assay (Aslantürk, 2017), etc.  MTT 
assay determines cell viability by measuring the activity of mitochondrial enzymes.  MTT is 
reduced to a purple formazan, and this compound is quantified by the light absorbance at 570 
nm.  Compared to MTT assay, MTS assay is a more efficient test since the produced 
formazan is more water-soluble and more sensitive to light absorbance.  Both MTT and MTS 
assays are simple, inexpensive, and safe tests, but it is reported that MTT and MTS assays 
will generate a relatively high variation of the cell viability results due to the variation of the 
mitochondrial enzyme activity (van Tonder, Joubert, & Cromarty, 2015; P. Wang, Henning, & 
Heber, 2010).  SRB assay provides more reliable cell viability results compared to MTT 
assay (van Tonder et al., 2015).  SRB binds to protein basic amino acid residues under mildly 
acidic conditions and dissociates under basic conditions.  The amount of binding SRB is 
proportional to the cell mass so that the cell viability can be determined by the light 
absorbance of SRB dye at 565 nm.  The limitation of the SRB assay is that it is not sensitive 
to the non-adherent cells because of the multiple washing steps during the assay.  
In this chapter, three aspects of cellular drug delivery will be studied for evaluating 
the contribution of binding affinity to targeting delivery.  Firstly, peptides should be able to 
bind to the receptor on the cell membrane.  The cellular binding assay will be conducted to 
show the cellular binding and selectivity of FITC-labeled peptides to different cell lines.  
Next, it is necessary to prove that peptides can be internalized into cells after binding to the 
receptor.  Observation of peptide cellular distribution and the uptake mechanism assays will 
be performed for this purpose.  Finally, the cytotoxicity in different cell lines will be 
compared between three PDCs to show their difference of drug delivery efficiency through 





Alexa-Fluor 594 wheat germ agglutinin, SlowFade® was purchased from Invitrogen 
(Carlsbad, CA, USA).  DMEM with 4.5 g/L Glucose, L-Glutamine, and Sodium pyruvate 
was purchased from VWR (Radnor, PA, USA).  Fetal bovine serum (FBS) and penicillin-
streptomycin were ordered from Gemini (Sacramento, CA, USA).  PBS and Hoechst 33342 
were ordered from Fisher Scientific (Waltham, MA, USA).  Trichloroacetic acid, acetic acid, 
and tris base were obtained from Chem-Impex International Inc. (Wood Dale, IL, USA).  
Sulforhodamine B (SRB) sodium salt powder, dynasore monohydrate, and methyl-β-
cyclodextrin were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).  All 
chemicals and reagents were used as received without further purifications.  MDA-MB 468, 
MCF-7 and HEK 293 cells were obtained from ATCC (Manassas, VA, USA).   
Methods 
Fluorescent Microscopy and Confocal Laser Scanning Microscopy  
Cellular binding and uptake studies of three peptides were performed in MDA-MB-
468, MCF-7, and HEK-293 cells.  In this study, MDA-MB-468 cells are considered the high 
EGFR-expressed cell line, MCF-7 cells are considered low EGFR-expressed cell line, and 
HEK-293 cells are considered EGFR-negative cell line (Subik et al., 2010).  Cells were 
cultured in T75 culture flasks using DMEM growth medium with 10% FBS and 1% 
penicillin-streptomycin in the 37 °C and 5% CO2 isothermal incubator.  One 
#
1.5 coverslip 
was put into each well of the 6-wells plate before seeding the cells.  Upon reaching the 80% 
confluency, cells were seeded into the 6-wells plate with a cell density of around 2× 10
5
 in 
each well.  The plate was placed in the incubator for 24 hours to let the cells attach to the 
plate.  Then cells were washed with PBS to remove the serum protein.  FITC-conjugated 
peptides were dissolved in serum-free cell culture media, which contains 0.5% DMSO.  The 
final concentration of peptides was adjusted to 20 μM.  In each well, 2 ml of peptide solution 
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was added and incubated for either 15 minutes or 25 minutes.  The cells were then washed 
with PBS twice and stained by Hoechst 33342 (1μg/ml) and Alexa fluor 594 (2.5 μg/ml) for 
10 minutes.  Afterward, the cells were washed with PBS twice and fixed with 4% 
paraformaldehyde solution for 15 minutes.  The coverslips were placed on the microscope 
slides to let the cells attach to the slides and sealed with the nail polish.  The stained cell 
slides were observed using the Keyence BZ-X710 (Itasca, IL, USA) and inverted Leica 
DMIRE2 confocal laser scanning microscope (Leica Biosystems Richmond Inc, Richmond, 
USA) with Yokogawa CSU-X1 confocal scanner unit.     
Cellular Uptake Mechanism Study 
The cellular uptake mechanism assays were conducted using confocal laser scanning 
microscopy with the following pre-treatments to the cells and samples.  For the energy-
dependent study, cells and the peptides were pre-incubated at 4°C for 30 minutes.  Then the 
FITC-labeled peptides were added to the 6-wells plates.  For the competitive inhibition study, 
30 μM GE11 peptide was pre-incubated with cells for 30 minutes.  Then 20 μM FTIC-labeled 
GE11 peptide was added into the cells.  For inhibitors study, 80 μM of dynasore or 5 mM 
methyl-β-Cyclodextrin (Santa Cruz Biotechnology, Inc. Dallas, TX) PBS solution was added 
into the 6-wells plate 1 hour before the addition of peptides.  The same procedure of confocal 
laser scanning microscopy and confocal image analysis were used as described in 3.3.1.  
The fluorescence intensity of confocal images was measured by using ImageJ 
software (Hartig, 2013).  The interested region was determined by the software and the 
fluorescence intensity of the selected interested region over the area was measured.  The 
maximum brightness of images was set between 10000 and 11000 and the minimum 
brightness was set between 500 and 1000.  The mean fluorescent intensity of the designated 
area of cells was used to compare between each group.  Ten cells were selected in each 
group.  
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Cell Viability Assay 
The cell viability assay was performed to compare the cytotoxicity of MMAE, PDCs, 
and peptides.  MDA-MB-468, MCF-7, and HEK293 cells were seeded in 96 wells plates with 
1.5×10
4
 cells per well.  The plates were placed in the incubator for 24 hours to let the cells 
attach to the plate.  MMAE, PDC, and peptides solutions were prepared in serial 
concentrations in complete cell culture media with less than 0.5% DMSO.  The cells were 
incubated for 3 days and fixed by adding 50 μl cold 10% TCA aqueous solution under 4°C 
for 1 hour.  Then the cells were washed with deionized water 5 times, and the plates were 
placed on the paper towels for air-drying.  After the plates were dried, a 0.4% (wt/vol) SRB 
solution was prepared using a 1% acetic acid aqueous solution and the cells were stained with 
SRB solution in the dark at room temperature for one hour.  Then the cells were rinsed 5 
times with 1% (vol/vol) acetic acid to remove the unbound dye.  The plates were placed on 
the paper towels for air-drying.  Tris base solution (200 μl, 10 mM) was added into each well 
and shook for 30 minutes using an orbital shaker.  The absorbance of SRB was determined at 
565 nm by using the Synergy
TM
 HT plate reader (BioTek, Winooski, VT, US).  The viability 
of cells was calculated using the following equation: 
               
         
          
      
where           is the absorbance of the control group after background correction and 
           is the absorbance of the sample after background correction.  The IC50 value was 
calculated using Graph Pad Prism 7.04 software (GraphPad Software Inc., CA, USA) with 
nonlinear regression dose-response - inhibition curve fit (variable slope four parameters). 
Results and Discussion 
Comparison of Cellular Binding Between Three Peptides  
The cellular binding was investigated in the EGFR-positive MDA-MB-468 cell line 
by using the fluorescence microscope.  The images of cellular binding of three FITC-
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conjugated peptides at 15 minutes were shown in Fig 3.1.  As shown in Fig 3.1A, the highest 
FITC fluorescence intensity in EGFR-positive cells was observed in the GE11 group.  
PEP11-FITC showed moderate fluorescence intensity while the fluorescence signal of L1-
FITC can barely be observed, as shown in Fig 3.1 B and Fig 3.1 C.  Similar results had been 
kept at 25 minutes, which was shown in Fig. 3.2.  GE11-FITC peptide had the highest 
fluorescence intensity, while L1-FITC peptide had the lowest fluorescence intensity.  These 
results indicated that GE11 had the highest cellular binding in the EGFR-positive cells while 
L1 had the least cellular binding.   
Cellular binding is the basis of the cellular trafficking and biological activity of 
peptides.  Peptides should be able to bind to the receptor on the cell membrane and trigger 
receptor-mediated endocytosis.  The highest binding affinity peptide GE11 has the most 
cellular binding to EGFR-positive cells, meaning that the peptide binding affinity to the 
receptor contributes to the cellular binding.  Moreover, the Kd values of GE11, PEP11, and 
L1 are 22 nM, 252nM, and 1.25μM, respectively, demonstrating that in EGFR-targeted drug 
delivery, the peptide with the binding affinity of 22 nM has stronger cellular binding than 


































Figure 3.1. Images of cellular uptake of three FITC-conjugated peptides in MDA-MB-468 
cells by using keyence fluorescence microscope at 15min. A. GE11-FITC. B. PEP11-FITC. 
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Figure 3.2. Images of cellular uptake of three FITC-conjugated peptides in MDA-MB-468 
cells by using keyence fluorescence microscope at 25min. A. GE11-FITC. B. PEP11-FITC. 
















The cellular binding results in EGFR-moderate expressed MCF-7 cells were shown in 
Fig 3.3 and Fig 3.4.  Overall, the fluorescence intensity of all FITC-labeled peptide groups in 
MCF-7 cells was lower than MDA-MB-468 cells at either 15min or 25min.  This result 
showed that the cellular binding level of FITC-labeled peptides corresponded to the cellular 
expression level of EGFR.  The significant FITC signal in the MCF-7 cell line only occurred 
in the GE11-FITC group at 25min, shown in Fig 3.4A.  At both 15min and 25min, GE11-
FITC showed the most cellular binding among three peptides in MCF-7 cells, which 
supported the idea that higher binding affinity peptides could contribute to more cellular 





















































Figure 3.3. Images of cellular uptake of three FITC-conjugated peptides in MCF-7 cells by 
using keyence fluorescence microscope at 15min. A. GE11-FITC. B. PEP11-FITC. C. L1-


































Figure 3.4. Images of cellular uptake of three FITC-conjugated peptides in MCF-7 cells by 
using keyence fluorescence microscope at 25min. A. GE11-FITC. B. PEP11-FITC. C. L1-















Next, we used a confocal laser scanning microscope to observe the cell binding of 
GE11 peptide in different cell lines.  The confocal laser scanning microscope is more 
sensitive compared to the fluorescence microscope.  Higher resolution images can be 
acquired from a confocal microscope.  The cellular binding images of GE11-FITC in EGFR 
high-expressed MDA-MB-468 cells, low EGFR-expressed MCF-7, and EGFR-negative 
HEK293 cells were shown in Fig 3.5, Fig 3.6, and Fig 3.7.  Among three cell lines, GE11-
FITC has the highest FITC signal in MDA-MB-468 cells, the low signal in MCF-7 cells, and 
no signal in HEK293 cells, which agrees with the expression level of EGFR.  This result also 
showed that GE11 could selectively bind to the EGFR-positive cells and respond to the 
























































Figure 3.6. Confocal images of the cellular uptake of GE11-FITC in EGFR-moderate 























































Cellular Distribution and Uptake Mechanism Study 
Upon binding to the cell surface, peptides need to be internalized into the cells to 
exhibit their biological activity.  To confirm that the peptides can be internalized into the 
cells, the cellular distribution of GE11-FITC was observed using a confocal microscope with 
a 63x microscope objective lens.  Since L1 did not show significant cellular binding and the 
cellular binding of PEP11 remained at a relatively low level, the high binding peptide GE11 
was used as the model peptide for the cellular distribution and mechanism study.  Fig 3.8 
showed the confocal images of GE11-FITC cellular distribution in MDA-MB-468 cells.  The 
result showed that at 15min higher FITC green fluorescence signal was found outside the 
membrane surface of cells.  The yellow signal was the merge color of the green signal of 
GE11-FITC and the red signal of the cell membrane, indicating that GE11-FITC was binding 
on the cell membrane.  While at 25 min, a more intense green signal in the FITC channel and 
a light yellow signal in the merged channel were shown inside the cell membrane, meaning 
that more peptides were internalized.  Based on these results, we can conclude that more 
peptides bind to the cell surface and get internalized at 25 minutes than 15 minutes.  The high 
magnification observation can clearly show the cellular distribution of peptides, but 
quantification of fluorescence intensity is not appropriate since the exact focus of cells is hard 





Figure 3.8. Comparison of cellular uptake of GE11-FITC in MDA-MB-468 cells between 
15min and 25min incubation time using 63x confocal microscope objectives. 
 
Once the peptide binds to the receptor, peptide-receptor interaction will trigger the 
endocytosis, and the receptor will be internalized into cells along with the peptide ligand.  
The cellular uptake inhibition studies were performed to validate the cellular uptake 
mechanism of peptides, and the results were shown in Fig 3.9.  The fluorescence intensity of 
GE11-FITC in MDA-MB-468 cells of each treatment group was normalized to that of 25min.   
Firstly, a non-FITC labeled GE11 peptide was added to the cells before adding the 
GE11-FITC.  Non-FITC labeled GE11 peptide will bind to EGFR and occupy the binding 
site of the receptor, acting as the competitive inhibitor to FITC labeled peptide.  The 
competitive binding of GE11 peptide is the basis of the EGFR-mediated active transport.  
According to the results, the cellular uptake of GE11-FITC was significantly inhibited after 
adding non-FITC labeled GE11 peptide, showing that GE11 peptide could competitively bind 
to EGFR.   












Next, the temperature-dependent cellular uptake study was conducted.  Active 
transport is an energy-dependent manner, and lower temperature will hamper the active 
transport of peptides.  As shown in Fig 3.9, the cellular uptake of GE11-FITC at 4°C was 
about 35% as it was at 37°C.  The cellular uptake of GE11-FITC is significantly inhibited by 
inhibiting the active transport of cells.  The 35% of GE11-FITC at 4°C possibly came from 
the passive diffusion and cellular binding. 
Two endocytosis inhibitors, dynasore and MBCD, were used to study the endocytosis 
mechanism of GE11.  Dynasore was used as an inhibitor of clathrin-mediated endocytosis 
and MBCD was used as an inhibitor of caveolae-mediated endocytosis (Kirchhausen et al., 
2008; Mahammad & Parmryd, 2015; Moriyama et al., 2007).  The results showed that the 
addition of MBCD inhibited the uptake of GE11-FITC by 55%, while dynasore did not 
significantly inhibit the cellular uptake of GE11-FITC, indicating that the cellular uptake 
mechanism of GE11 was possibly the caveolae-mediated endocytosis.  The rapid clathrin-
mediated endocytosis is believed to be the major internalization mechanism of EGFR when 
EGFR is activated by the ligand (Burke, Schooler, & Wiley, 2001; Tomas et al., 2014).  It has 
been reported that GE11 does not effectively activate EGFR to undergo clathrin-independent 
endocytosis(Zonghai Li et al., 2005; Sachdeva et al.  Moreover, one study showed that 
depletion of dynamin would inhibit the endocytosis of EGFR without affecting the binding of 
EGF (Sousa et al., 2012).  This means that the GE11 peptide can still bind to EGFR without 
internalized into the cell, causing the relatively high green fluorescence intensity in the 
dynasore group.  Besides, it has been reported that MBCD can also inhibit clathrin-mediated 
endocytosis by inhibiting the formation of the clathrin-coated endocytic vesicles (Joshi et al., 
2016).  The mechanism of EGFR uptake may include both clathrin-mediated and caveolae-
mediated endocytosis.  Thus, MBCD can inhibit the uptake of GE11-FITC, while dynasore 
cannot inhibit the uptake of GE11-FITC solely based on the inhibition of clathrin-mediated 
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endocytosis.  In conclusion, the uptake mechanism study of GE11 reveals that the cellular 
uptake of GE11 is via energy-dependent endocytosis, but the specific mechanism of 
endocytosis still needs more investigation.   
The cellular internalization of the FITC fluorescence probe was compared with FITC 
labeled GE11 peptide to show the integrity of the FITC-labeled peptide during the incubation.  
As a small molecule, the cellular internalization mechanism of FITC is passive diffusion.  
FITC showed much higher fluorescence signals compared to GE11 peptide, which was 
shown in Fig 3.9.  The comparison between the FITC and GE11-FITC peptide demonstrates 
that the internalization mechanism of FITC is altered by conjugating to GE11 peptide.  This 
difference also provides evidence of the integrity of the FITC-labeled GE11 peptide during 
the experiment.  In summary, GE11 peptide can successfully be internalized into MDA-MB-
468 cells.  The uptake mechanism of the GE11 peptide is energy-dependent endocytosis, 






Figure 3.9. Results of cellular uptake mechanism analysis in MDA-MB-468 cells. Using 
GE11-FITC as model peptide incubated with the addition of Dyn, MBCD, and free GE11 
peptide. The comparison was also conducted between incubation temperature of 4°C and 
37°C, FITC labeled GE11 peptide and FITC. *: p<0.01 calculated by one-way ANOVA. 
 
Comparison of Cytotoxicity Between Three PDCs 
When the peptide is internalized into the cells, the cytotoxic drug should be 
simultaneously delivered into the cells by conjugating with the peptide.  The cytotoxicity 
assays were conducted to differentiate the drug delivery efficiency of three PDCs.  MDA-
MB-468 cells, MCF-7 cells, and HEK293 cells were used in this study as the cell lines with 
EGFR expression from high to low.  The cytotoxicity of three PDCs and free drug MMAE in 
three cell lines were shown in Fig 3.10 and Fig 3.11.  The IC50 values of all PDCs were 
summarized in Table 3.1.  For MDA-MB-468 cells, GE11-MMAE showed the lowest IC50 
value as 100 times lower than MMAE, representing the highest drug delivery efficiency of 
three peptides.  In the MCF-7 cells, both GE11-MMAE and PEP11-MMAE enhanced the 
cytotoxicity compared to MMAE, while L1-MMAE and MMAE did not show significant 





































significant difference.  The cytotoxicity results of unconjugated peptides were also conducted 
and the results were shown in Fig 3.11.  All the unconjugated peptides did not show 
significant cytotoxicity to all three cell lines, which meant peptides did not play a role in 
killing tumor cells.     
The cytotoxicity study results (Fig 3.10) reveal that GE11-MMAE has significantly 
higher cytotoxicity to MDA-MB-468 cells and MCF-7 cells than MMAE.  This means that 
GE11 can enhance the drug delivery into the EGFR-expressed cells and release the drug in 
the cells.  The significant difference of IC50 value between GE11-MMAE and MMAE was 
found in MDA-MB-468 cells and MCF-7 cells, but not in HEK-293 cells.  This result 
indicates that GE11 can selectively deliver the drug to EGFR-expressed cells.  The IC50 
value of GE11-MMAE in MCF-7 cells was 6 times higher than MDA-MB-468 cells, which is 
possibly due to the lower EGFR expression in MCF-7 cells.  PEP11-MMAE shows a 
significant difference in MCF-7 cells, but the negligible difference to MMAE in MDA-MB-
468 and HEK293 cells.  Compared to GE11 peptide, PEP11 peptide has a weaker binding 
affinity to EGFR, resulting in less drug delivery efficiency and selectivity to EGFR-positive 
cells.  The L1-MMAE does not show a difference with MMAE in all cell lines, indicating 
that L1-MMAE cannot enhance the drug delivery through an active targeting effect.  This 
result showed that the drug delivery efficiency could be improved when the binding affinity 
of peptide ligands was in the nanomolar range. 
Among three PDCs, the lowest IC50 value was found in GE11-MMAE to MDA-MB-
468 cells, indicating the highest targeted drug delivery efficiency to EGFR-positive cells.  
GE11-MMAE showed the most significant difference of IC50 value, which was more than 
1000 times lower in MDA-MB-468 cells than HEK-293 cells.  Therefore, GE11-MMAE has 
the highest selectivity among the three PDCs.  Based on these results, GE11, as the highest 
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binding affinity peptide, can induce the highest drug delivery efficiency and selectivity to 
EGFR-positive cells among three peptides.     






















































































Figure 3.10. Cytotoxicity in MDA-MB-468, MCF-7, and HEK293 cells of PDCs. 
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Figure 3.11. Cytotoxicity in MDA-MB-468, MCF-7, and HEK293 cells of peptides. 
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Table 3.1  
IC50 Values of Three PDCs in Three Cell Lines. *:p<0.05 compared to MMAE 
Cell line 
 IC50(nM)  
MDA-MB-468 MCF-7 HEK293 
MMAE 18.1±7.5 255±99 1.67×10
3
±539 
L1-MMAE 55.9±17.8 305±102 52.1±18.6 
PEP11-MMAE 14.3±4.1 23.8±6.6* 142±35 
GE11-MMAE 0.171±0.034* 1.01±0.26* 288±97 
 
In conclusion, the cellular targeting delivery of three peptides was studied in three 
aspects in this chapter. The cellular binding assay results showed that the highest binding 
affinity peptide GE11 had the most cellular binding to EGFR-positive cells.  The cellular 
uptake and uptake mechanism study showed that GE11 peptide could be internalized into the 
cells through receptor-mediated endocytosis.  Finally, we used the cell viability assay to see if 
peptides could successfully and selectively deliver the drug into target cells.  And we found 
out that among all three PDCs and MMAE, GE11-MMAE had the highest drug delivery 
efficiency to the EGFR-positive cells and the highest selectivity between EGFR-positive and 
negative cells.  Overall, the binding affinity of peptide ligand can contribute to more cellular 
binding to the target cells, leading to more cellular uptake into the cells.  The cytotoxicity 
assay also indicates that binding affinity contributes to more drug delivery into the cells.  This 
enhanced cellular uptake of the peptide may be due to the higher cellular uptake rate induced 
by the higher binding affinity.  The time profile of peptide cellular uptake will be acquired to 









 Binding affinity is one major factor in ligand-receptor kinetics.  One-step binding and 
two-step binding models are typically used to characterize the binding of ligand to the target 
(AP & Guo, 2019; Copeland et al., 2006; Hulme & Trevethick, 2010).  One-step binding 
model is described as ligand binding to the receptor to form the binary complex and 
dissociated from the receptor by merely one step, as shown in the equation below:   
                                                                                         
where kon is the association rate constant, and koff is the dissociation rate constant.   
The two-step binding model considers the conformation change of the receptor 
leading to a higher binding affinity for the ligands.  
                                                                                                         





    
   
    
The binding affinity of peptide to the target is defined by the equilibrium dissociation 
constant KD.  KD represents the ligand concentration when 50% of the receptor is occupied.  
A lower KD value leads to a higher ratio of binding ligands to the receptor, meaning higher 
binding affinity.  A higher association rate or lower dissociation rate can result in lower KD 
and higher binding affinity.  The association rate constant determines how fast the ligand 
binding to the receptor.  However, the association rate constant is usually less considered in 
ligand binding than the dissociation rate constant since the association process is thought to 








the receptor can induce faster drug efficacy, there is a lack of medicinal chemistry methods to 
overcome the limit of diffusion (Copeland et al., 2006).   
Dissociate rate constant is thought to be the determinant factor for the retention time 
of ligand.  The retention time of ligand-receptor interactions is raised as a significant factor in 
drug delivery.  The longer retention time of ligand-receptor interaction has been reported to 
be beneficial to the biological function and the clinical outcome (Sykes et al., 2017; 
Vauquelin, 2018).  Wood et al. used EGFR inhibitors to investigate the recovery time of 
EGFR activity.  They found that the activity of EGFR needs at least 24 hours to be fully 
recovered after the inhibitor was removed, which was due to the slow dissociation rate of the 
inhibitor from the receptor (Wood et al., 2004).  The prolonged cellular efficacy was 
consequently achieved by the extended inhibition of EGFR.  
It was reported that the kinetics of EGFR-mediated internalization followed the 
Michaelis-Menten kinetics (Masui, Castro, & Mendelsohn, 1993).  Michaelis-Menten 
kinetics is expressed as:  
  
     [  ]
   [  ]
 
       is the maximum rate of internalization,    is the Michaelis constant, v is the 
internalization rate, and [  ] is the concentration of the binding ligand.  If the internalization 





Figure 4.1. Schematic of Michaelis-Menten kinetics curve 
 
Above all, binding affinity contributes to more binding ligands.  More binding ligands 
may induce a higher rate of cellular uptake.  In this study, the time profile of peptide cellular 
uptake will be compared to gain a better understanding of how binding affinity contributes to 
cellular uptake. 
Material and Methods 
The sample treatment and analysis method were the same as described in 3.3.1.  
Briefly, coverslips were placed inside the 6-wells plates.  MDA-MB-468 cells were seeded 
onto coverslips with a cell density of around 2× 10
5 
in each well.  The plate was placed in the 
incubator for 24 hours to let the cells attach to the plate.  Then cells were washed with PBS to 
remove the serum protein.  Then FITC-conjugated peptides were incubated with cells for 5, 
10, 15, 25, 30, and 45 minutes, respectively.  At each time point, the peptide solution was 
removed.  Then cells were washed with PBS and fixed with 4% formaldehyde.  The 
suspended cells were further stained with Hoechst 33342.  The coverslips were taken out 
from the wells and transferred on the slides with cells attached to the slides.  The slides were 
stored in the 4℃ refrigerator and observed using the confocal laser scanning microscope the 
next day.  The semi-quantification analysis was conducted by using ImageJ.  The average 
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fluorescence intensity over the designated area of a single cell was determined by ImageJ.  
Ten cells were selected from each peptide group and each time point. 
Results and Discussion 
Cellular uptake kinetics study was conducted using FITC-labeled GE11 and PEP11 
peptides in MDA-MB-468 cell lines, as L1 peptide did not exhibit significant uptake as 
shown in chapter 3.3.1.  The results were shown in Fig 4.2 and Fig 4.3.  The result of the 
semi-quantitative analysis was shown in Fig 4.4.  Before 10 minutes, no significant uptake of 
both peptides was observed in cells.  At 15 minutes, the fluorescence intensity was increased 
dramatically by 123% for GE11-FITC and 105% for PEP11-FITC.  For GE11-FITC, the 
fluorescence intensity was increased by 78% from 15 minutes to 30 minutes and 13% from 
30 minutes to 45 minutes.  For PEP11-FITC, the fluorescence intensity was increased by 35% 
from 15 minutes to 30 minutes and 16% from 30 minutes to 45 minutes.  Both peptides 
showed a rapid uptake rate before 25 minutes and a slower uptake rate after 30 minutes.  
PEP11-FITC initially got comparable cellular uptake compared to GE11-FITC at 15 minutes 
but got much less uptake after 25 minutes.  The cellular uptake of GE11-FITC was about 






























      
Figure 4.2. Images of cellular uptake kinetics study of GE11-FITC in EGFR-positive MDA-
MB-468 cells using the confocal microscope. Incubation time: A. 5min. B. 10min. C. 15min. 
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Figure 4.3. Images of cellular uptake kinetics study of PEP11-FITC in EGFR-positive MDA-
MB-468 cells using the confocal microscope. Incubation time: A. 5min. B. 10min. C. 15min. 
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Figure 4.4. Semi-quantitative analysis of the cellular uptake kinetics with different incubation 
time in MDA-MB-468 cells 
 
The detectable cellular uptake of both peptides was observed after 15 minutes.  The 
absence of peptide cellular uptake before 15 minutes is mostly due to the detection limit of 
the microscope.  The diffusion of peptides insolvent and binding to the receptor will take time 
to achieve the detectable amount of peptides under the microscope.  The detectable 
endocytosis of peptides was reported as early as 10 minutes but with no detection before 5 
minutes (Magadan, Barbieri, Mesa, Stahl, & Mayorga, 2006).    
After 15min, both peptides started to show the fluorescence signal, indicating that 
peptides bound and got uptake by the cells.  The fluorescence intensity represented the 
accumulated amount of the cellular uptake of peptides.  At each time point after 15min, 
GE11-FITC showed higher fluorescence intensity than PEP11-FITC, revealing that GE11-
FITC got more cellular uptake than PEP11-FITC.  Higher binding affinity peptide GE11 
showed a higher rate of cellular uptake compared to the lower binding peptide.  The possible 
reason is the higher concentration of binding ligand-induced by the higher binding affinity.  
As stated in Chapter 4.1, binding affinity contributes to the binding ligand concentration.  A 




































peptides undertake a similar endocytic pathway.  For the peptides in our study, GE11 and 
PEP11 do not effectively activate EGFR (Zonghai Li et al., 2005; Sachdeva et al., 2019).  So 
we can assume that the internalization rate of GE11 and PEP11 peptides mainly depends on 
the concentration of the binding ligand.  As a result, binding affinity contributes to higher 
binding ligand concentration, leading to a higher internalization rate of cellular uptake.  The 
rapid cellular uptake is beneficial to drug delivery because the time for ligand and receptor 
contact is limited in vivo.  More rapid cellular uptake of peptides can induce higher drug 
delivery efficiency.  In this way, binding affinity can contribute to drug delivery by elevating 


















CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
Ligand-based targeted drug delivery can selectively deliver drug into the target cells 
by the ligand-receptor interaction.  The binding affinity between the receptor and ligand is the 
key factor in targeted drug delivery.  Efforts have been made to increase the binding affinity 
of peptides to the receptor, assuming that higher binding affinity can contribute to more 
efficient drug delivery (Hossein-Nejad-Ariani, Althagafi, & Kaur, 2019; Newman & Benoit, 
2018; Spiliotopoulos et al., 2019).  However, binding affinity may not always contribute to 
the targeted drug delivery and the high binding affinity peptide ligands are not always 
accessible.  There is a lack of knowledge on the relationship between binding affinity and the 
targeted drug delivery in the peptide-based drug delivery system.  Thus, it is necessary to 
explore the optimized range of binding affinity for peptide ligands.   
In this study, it is hypothesized that the binding affinity of peptide ligand has an 
optimal range with a minimum threshold and a maximum limit for effective targeted drug 
delivery.  Three EGFR-targeting peptides with binding affinities ranging from micromolar to 
nanomolar were selected.  Their cellular EGFR selectivity, binding, internalization, 
cytotoxicity of PDC, and cellular binding kinetics were studied to investigate how binding 
affinity would contribute to the targeting delivery.  This is the first time study to compare the 
targeting delivery efficiency between peptides with different binding affinities and determine 
their potential in the targeted drug delivery.    
The cellular uptake of the peptide can be divided into three steps, binding, 
internalization, and exerting cytotoxicity.  Therefore, to kill the cancer cells, a peptide needs 
to first bind to the receptor on the target cellular membrane.  Using the fluorescent probe, 
GE11-FITC showed the strongest cellular binding among three peptides.  PEP11-FITC 
showed less binding compared to GE11-FTIC but showed stronger binding than L1-FITC.  
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GE11-FITC also showed the selectivity of cellular binding between EGFR-positive cells and 
EGFR-negative cells.  The results of cellular binding suggested that binding affinity could 
contribute to the specific cellular binding of peptide ligands. 
After binding to the cell surface, peptides should be internalized into the cells serving 
as a targeting moiety for drug delivery.  The internalization and uptake mechanism of peptide 
assays were performed to prove that GE11 peptide could be uptake by the cells through 
receptor-mediated endocytosis.  The observation of fluorescence distribution showed that 
GE11 peptide was able to be internalized into the cells.  The temperature-dependent uptake 
study showed that the uptake of GE11-FITC could be inhibited by the low temperature, 
indicating that the cellular uptake of GE11 peptide was active transport.  Besides, the uptake 
of GE11-FITC could also be inhibited by the free peptide and MBCD, which showed that the 
uptake mechanism of GE11 peptide was receptor-mediated endocytosis.  In conclusion, the 
uptake mechanism studies showed that GE11 peptide could be successfully internalized into 
cells through receptor-mediated endocytosis.   
Once the peptide-drug conjugate is internalized into cells, drug should be released 
into the cells and kill tumor cells.  To investigate the drug delivery efficiency, three peptides 
were conjugated to a nonselective cytotoxicity drug, MMAE, through a protease-sensitive 
linker.  The cytotoxicity assay results showed that GE11-MMAE had the lowest IC50 value 
for EGFR-positive cells among all the PDCs and MMAE.  Furthermore, the IC50 of three 
PDCs and MMAE did not show the difference in the EGFR-negative cells, indicating that 
GE11-MMAE had the highest selectively in killing tumor cells.  PEP11-MMAE showed 
lower drug delivery efficiency to the EGFR-positive cells than GE11-MMAE but still 
enhanced the cytotoxicity than MMAE.  L1-MMAE with an affinity in the range of 
micromole failed to enhance the drug delivery compared to MMAE.  The results suggested 
that to enhance the drug delivery, the binding affinity should fall in the range of nanomolar, 
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and higher binding affinity would contribute to the higher efficiency of cytotoxic agent 
delivery. 
To understand the contribution of binding affinity to the cellular uptake, the rate of 
cellular uptake was compared between GE11 and PEP11 peptides.  GE11 peptide showed 
about 40% more cellular uptake than PEP11 at 45min, indicating that binding affinity could 
contribute to the rate of cellular uptake.  The enhanced cellular uptake rate could be attributed 
to the higher dynamic concentration of bond ligand due to the higher binding affinity.   
In conclusion, this study probed the relationship of binding affinity and the efficiency 
of targeted intracellular delivery of anticancer agents using the peptides, fluorescence-labeled 
peptides, and PDCs that bind to the EGFR.  Three peptides with different levels of binding 
affinity ranging from micromolar to nanomolar were used to demonstrate how binding 
affinity contributed to the EGFR-targeting delivery by delineating the binding selectivity, 
binding affinity, and cellular internalization and uptake kinetics using fluorescence-labeled 
peptides and PDC.  In general, the trend is higher binding affinity can contribute to higher 
cellular binding, drug delivery efficiency and selectivity, and a higher rate of cellular uptake.  
To achieve a meaningful targeting efficiency, the binding affinity of peptide ligands for 
EGFR-targeted drug delivery should fall in the range of nanomolar.  This study can serve as a 
starting point for further studies to reveal the quantitative relationships between binding 
affinity and targeting efficiency, which could provide fundamental information for the design 
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